Huons Meditech showcases innovations at conferences in New Delhi and Jakarta
Published: 30 Oct. 2024, 00:00
![Huons Meditech participated in ICAP 2024 held in Jakarta, Indonesia, and is conducted promotional activities by detailing its products to attendees. [HUONS GLOBAL]](https://koreajoongangdaily.joins.com/data/photo/2024/10/30/b4dbc585-6b6e-4d19-a16e-d4cdea8e312a.jpg)
Huons Meditech participated in ICAP 2024 held in Jakarta, Indonesia, and is conducted promotional activities by detailing its products to attendees. [HUONS GLOBAL]
Huons Meditech, under the leadership of CEO Lee Jin-suk, participated in the 2024 Congress of the Société Internationale d’Urologie (SIU 2024) in New Delhi, India, from Oct. 23 to 26.
Through this event, the company aimed to demonstrate its advanced technology and strengthen its competitive presence on the global stage.
SIU, established in 1907, is one of the most distinguished international platforms focused on urological diseases and treatments, drawing thousands of experts from more than 100 countries each year. Attendees engage in sessions and exhibitions discussing the latest technological advancements and treatment methods shaping global urology.
At SIU 2024, Huons Meditech showcased its URO-UEMXD, an extracorporeal shock wave lithotripter (ESWL) that combines a shock wave head with an inline ultrasound probe, setting it apart from traditional X-ray-based devices. This approach enables both diagnosis and treatment of opaque and non-opaque urinary stones through ultrasound, allowing for heightened precision and minimizing reliance on X-ray imaging. The URO-UEMXD, developed in collaboration with India’s Vasu Group, was well-received at the event, underscoring Huons Meditech’s intention to capture a substantial portion of the global urology market.
Further enhancing the company’s impact, Prof. Yoon Hana, Korea’s first female urologist, presented on “The Current Trend of ESWL in Urolithiasis.” Her discussion emphasized the URO-UEMXD’s clinical efficacy and safety, supporting these claims with research findings that highlighted improved treatment outcomes and patient comfort.
In addition to SIU 2024, Huons Meditech participated in the International Congress of ASLS & Perdaweri Banten (ICAP 2024) in Jakarta, Indonesia. There, the focus shifted to strengthening the company’s influence in the global beauty device market, underscoring Huons Meditech’s diverse portfolio and international ambitions.
CEO Lee said that participating in these prominent international conferences has provided Huons Meditech with valuable exposure and networking opportunities, furthering the company’s reach in both the Indian and Indonesian markets. Emphasizing collaboration with global partners, he expressed the company’s commitment to actively expand its market share through strategic partnerships and continued innovation.
BY KIM YEONSOO [kim.yeonsoo1@joongang.co.kr]
What is “Promoted Content”?
“Promoted Content” articles are written by our staff reporters. They are promoted to some extent by an external company.
Promoted Content is not the same as “Guest Reports,” which are paid advertorials.
Our reporters and editors retain complete editorial independence in the conception and production of Promoted Content.
“Promoted Content” articles are written by our staff reporters. They are promoted to some extent by an external company.
Promoted Content is not the same as “Guest Reports,” which are paid advertorials.
Our reporters and editors retain complete editorial independence in the conception and production of Promoted Content.
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)